Show simple item record

dc.contributor.authorMorgan, R
dc.contributor.authorEl-Tanani, M
dc.contributor.authorHunter, KD
dc.contributor.authorHarrington, KJ
dc.contributor.authorPandha, HS
dc.date.accessioned2017-07-14T10:45:40Z
dc.date.issued2017-05-09
dc.identifier.citationOncotarget, 2017, 8 (19), pp. 32322 - 32331
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/703
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.15971
dc.description.abstractThe HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also dysregulated in a wide range of solid and haematological malignancies and have a predominantly pro-oncogenic function. A key mode of transcriptional regulation by HOX and PBX proteins is through their interaction as a heterodimer or larger complex that enhances their binding affinity and specificity for DNA, and there is growing evidence that this interaction is a potential therapeutic target in malignancies that include prostate, breast, renal, ovarian and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its application in precision medicine.
dc.formatPrint
dc.format.extent32322 - 32331
dc.languageeng
dc.language.isoeng
dc.publisherIMPACT JOURNALS LLC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectCell Transformation, Neoplastic
dc.subjectHomeodomain Proteins
dc.subjectProtein Binding
dc.subjectMultigene Family
dc.subjectProtein Multimerization
dc.subjectMolecular Targeted Therapy
dc.subjectBiomarkers
dc.titleTargeting HOX/PBX dimers in cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-02-23
rioxxterms.versionofrecord10.18632/oncotarget.15971
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue19
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume8
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0